

Randomized multicenter open trial.
Patients with CD having surgery with ileocolonic anastomosis or colo-colonic anastomosis were randomized to IFX 5mg/kg (0,2,6 and q8w) or control arm.
5ASA or elemental diet postsurgery were possible.

Primary endpoints: Endoscopic or clinical recurrence in 2 years.

Results:

- Disease recurrence rate IFX 52.6% vs 94.7% in the control group, $p < 0.05$

Conclusion:

The postoperative use of IFX is effective in preventing Crohn's disease recurrence for 2 years.




Fig. 2 The recurrence rate after 2 years. The disease recurrence rate in the infliximab group was significantly lower than that in the non-infliximab group